Fujifilm to Invest Over 200 Billion yen (2 Billion USD) to Establish New Large-Scale Cell Culture Manufacturing Site for Biopharmaceuticals in the U.S.A.

Share this article
Share this article
TOKYO, Jan. 6, 2021 /PRNewswire/ -- FUJIFILM Corporation (President: Kenji Sukeno) is making an investment of more than 200 Billion yen (2 Billion USD) to establish a new large-scale cell culture production site in the United States to accelerate the growth of its biopharmaceutical contract development and manufacturing business (CDMO).
FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation, with development and manufacturing facilities across the U.S.A., U.K., and Denmark will operate the new facility. This new facility will offer large-scale cell culture manufacturing of bulk drug substance with 8 x 20,000L bioreactors (physical volume), with the potential to expand and add a further 24 x 20,000L bioreactors based on market demand. In addition to drug substance manufacture, the facility will also provide commercial scale, automated fill-finish and assembly, packaging and labeling services. The new site will be built within the vicinity of an existing Fujifilm site, and is scheduled to begin operations in the spring of 2025.

Related Keywords

Japan , Tokyo , United States , Denmark , North Carolina , United Kingdom , Texas , Martin Meeson , Kenji Sukeno , Diosynth Biotechnologie Hiller , Holdings Corporation , Biologics Contract Development , Fujifilm , Mitsubishi Corporation , Manufacturing Organization , United Statesa , Biotechnologie Hiller , College Station , Fujifilm Diosynth Biotechnologies , ஜப்பான் , டோக்கியோ , ஒன்றுபட்டது மாநிலங்களில் , டென்மார்க் , வடக்கு கரோலினா , ஒன்றுபட்டது கிஂக்டம் , டெக்சாஸ் , ஹோல்டிங்ஸ் நிறுவனம் , உயிரியல் ஒப்பந்த வளர்ச்சி , புஜிஃபில்ம் , மிட்‌ஸ்யூபீஶி நிறுவனம் , உற்பத்தி ஆர்கநைஸேஶந் , கல்லூரி நிலையம் ,